
Vertex’s Orkambi can be used in even younger cystic fibrosis patients, says European Commission
pharmafile | January 22, 2019 | News story | Manufacturing and Production, Sales and Marketing | Orkambi, Vertex, cystic fibrosis, pharma
Vertex has announced that the European Commission has decided to approve a label extension in the region for Orkambi (lumacaftor/ivacaftor) in the treatment of cystic fibrosis (CF), expanding the pool of eligible patients to include children aged between two and five years of age who have two copies of the F508del mutation.
The ruling follows a positive CHMP opinion for the therapy back in November. The drug was originally approved in Europe in the same indication for patients older than 12, with an extension to this coming in January 2018 to include paediatric patients aged between six and 11.
The latest decision was made on the back of Phase 3 data derived from 60 patients which demonstrated that Orkambi’s safety profile in these younger patients remained consistent with data observed in patients older than six, and that the therapy was generally well tolerated over a treatment duration of 24 weeks.
“Today’s approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF,” said Dr Reshma Kewalramani, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. ‘‘By treating the underlying cause of disease early, we can potentially modify its course and offer patients the chance of improved outcomes.’’
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Vertex presents promising new data from cystic fibrosis trials
Vertex Pharmaceuticals has presented new data showing the clinical and quality-of-life benefits of its cystic …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …






